Skip to content

The effect study of treament of triple negative breast cancer by integrated traditional and western medicine

The effect study of treament of triple negative breast cancer by integrated traditional and western medicine

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-16008590
Enrollment
Unknown
Registered
2016-06-03
Start date
2016-07-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

triple negative breast cancer

Interventions

The integrated traditional and western medicine group:Standard western medicine treatment with traditional Chinese medicine therapy
The western medicine group:Standard western medicine treatment only

Sponsors

Longhua Hospital Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Primary breast cancer after surgical treatment, by pathological examination diagnosis for breast malignant epithelial tumors (breast cancer)IHC: ER(-)PR(-), Her-2(-); (2) The group completed from before chemotherapy or the completion of chemotherapy period was not more than 3 months, confirmed no recurrence or metastasis of the tumor; (3) KPS score>=60; (4) Female patients aged 18~75 years the expeted survival >6 months; (5) No severe organic or functional diseases, drug and food allergies; (6) Willing to accept treatment, observation and the check.

Exclusion criteria

Exclusion criteria: (1) Do not meet the inclusion criteria; (2) Tumor markers continuous elevation or find basin or abdominal cavity viscera have not clear diagnosis of lump, or PET tips with recurrence metastasis; (3) Patients with obstruction can't take Chinese traditional medicine; (4) Pregnant and lactating women; (5) Allergic constitution, and a variety of drug allergy; (6) A serious disease of heart, liver, kidney and hematopoietic system and mental illness patients; (7) Patients were undergoing other drug test.

Design outcomes

Primary

MeasureTime frame
progression-free survival;

Secondary

MeasureTime frame
quality of life;tumor marker;Immunity;traditional Chinese medicine symptom;

Countries

China

Contacts

Public ContactLiu Sheng

Longhua Hospital Shanghai University of Traditional Chinese Medicine

lshtcm@163.com+86 021-64385700

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 12, 2026